United Therapeutics (UTHR) Research & Development (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Research & Development data on file, last reported at $138.2 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 7.25% year-over-year to $138.2 million; the trailing twelve-month figure through Mar 2026 stood at $539.2 million (up 2.53% YoY), and the FY2025 full-year result was $550.0 million, up 14.35% from the prior year.
• Research & Development slipped to $138.2 million in Q1 2026, from $139.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $151.4 million in Q4 2023 to a low of $66.1 million in Q3 2022.
• A 5-year average of $111.8 million and a median of $104.1 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development tumbled 77.28% in 2022 and soared 61.24% in 2023, its largest moves.
• Tracing UTHR's Research & Development over 5 years: stood at $93.9 million in 2022, then soared by 61.24% to $151.4 million in 2023, then dropped by 11.62% to $133.8 million in 2024, then gained by 4.26% to $139.5 million in 2025, then dropped by 0.93% to $138.2 million in 2026.
• Business Quant data shows UTHR's Research & Development at $138.2 million in Q1 2026, $139.5 million in Q4 2025, and $127.5 million in Q3 2025.